Waters Laura, Nelson Mark
Department of GU & HIV Medicine, Chelsea & Westminster Hospital, London, UK.
Curr Opin Infect Dis. 2006 Dec;19(6):615-22. doi: 10.1097/QCO.0b013e328010a869.
There is an urgent need for new anti-hepatitis C virus therapies and recently a number of agents have reached clinical trials with yet more in preclinical stages of development. New technologies for the in-vitro study of drugs have accelerated progress markedly, previously hampered by the lack of cell-culture systems or animal models for hepatitis C.
A number of agents have demonstrated potent antiviral activity and synergism with existing therapies. A better understanding of managing adverse events and tailoring treatment dose and duration have yielded improved treatment response rates. We review the mechanisms of both new and existing anti-hepatitis C virus drugs and the data for some promising new agents and strategies.
Although many of the agents reviewed are in the early stages of development they show great promise and the ever-increasing understanding of hepatitis C virus will undoubtedly lead to exploration of new targets. Much progress has been made in terms of maximizing success with currently licensed agents and lessons learned from the field of HIV can guide the careful use of new agents to minimize resistance in the future.
迫切需要新的抗丙型肝炎病毒疗法，最近一些药物已进入临床试验阶段，还有更多药物处于临床前研发阶段。此前，丙型肝炎缺乏细胞培养系统或动物模型，阻碍了药物体外研究的进展，而新技术显著加速了这一进程。
一些药物已显示出强大的抗病毒活性以及与现有疗法的协同作用。对不良事件管理以及治疗剂量和疗程调整的更深入理解提高了治疗反应率。我们综述了新型和现有抗丙型肝炎病毒药物的作用机制以及一些有前景的新药物和策略的数据。
尽管所综述的许多药物尚处于研发早期阶段，但它们显示出巨大潜力，而且对丙型肝炎病毒的认识不断加深无疑将促使探索新的靶点。在使现有获批药物的疗效最大化方面已取得很大进展，并且从艾滋病领域汲取的经验教训可指导谨慎使用新药物，以在未来尽量减少耐药性。
